{"id":"NCT01578239","sponsor":"Advanced Accelerator Applications","briefTitle":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","officialTitle":"A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09-06","primaryCompletion":"2015-07-31","completion":"2021-01-18","firstPosted":"2012-04-16","resultsPosted":"2017-10-02","lastUpdate":"2022-04-04"},"enrollment":231,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoid Tumor of the Small Bowel","Neuroendocrine Tumour"],"interventions":[{"type":"DRUG","name":"Octreotide LAR","otherNames":["SANDOSTATIN LAR, Octreotide"]},{"type":"DRUG","name":"177Lu-DOTA0-Tyr3-Octreotate","otherNames":["Lutathera"]}],"arms":[{"label":"177Lu-DOTA0-Tyr3-Octreotate","type":"EXPERIMENTAL"},{"label":"Octreotide LAR","type":"ACTIVE_COMPARATOR"}],"summary":"This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with metastasized or locally advanced, inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours with progression despite LAR treatment.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first until Primary Analysis cutoff date reached on 24July2015, assessed up to approximately 34 months","effectByArm":[{"arm":"177Lu-DOTA0-Tyr3-Octreotate","deltaMin":null,"sd":null},{"arm":"Octreotide LAR","deltaMin":8.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":39,"countries":["United States","Belgium","France","Germany","Italy","Portugal","Spain","United Kingdom"]},"refs":{"pmids":["34793718","32123969","29878866","28076709"],"seeAlso":["https://pubmed.ncbi.nlm.nih.gov/29878866"]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":111},"commonTop":["Nausea","Fatigue","Vomiting","Diarrhoea","Abdominal pain"]}}